Vaquero-Lorenzo C.
41
Coauthors
5
Documentos
Volumen de publicaciones por año
Cargando gráfico
| Año de publicación | Num. Publicaciones |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
Publicaciones por áreas de conocimiento
Cargando gráfico
| Área de conocimiento | Num. Publicaciones |
|---|---|
| Genética | 3 |
| Farmacología | 3 |
| Psicopatología | 2 |
| Medicamento | 2 |
| Salud mental | 1 |
Publicaciones por áreas temáticas
Cargando gráfico
| Área temática | Num. Publicaciones |
|---|---|
| Enfermedades | 3 |
| Problemas sociales y servicios a grupos | 2 |
| Farmacología y terapéutica | 2 |
| Fisiología humana | 1 |
| Bioquímica | 1 |
| Medicina y salud | 1 |
Principales fuentes de datos
| Origen | Num. Publicaciones |
|---|---|
| Scopus | 5 |
| Google Scholar | 0 |
| RRAAE | 0 |
Cargando gráfico
Coautores destacados por número de publicaciones
| Coautor | Num. Publicaciones |
|---|---|
| Adrián LLerena | 5 |
| Dorado P. | 5 |
| Baca-García E. | 3 |
| Almoguera B. | 3 |
| Ayuso C. | 3 |
| Fernandez-Piqueras J. | 3 |
| Abad-Santos F. | 3 |
| Dal-Ré R. | 3 |
| Riveiro-Alvarez R. | 3 |
| Lopez-Castroman J. | 2 |
Cargando gráfico
Top Keywords
Cargando gráfico
Publicaciones del autor
CYP2D6 and the severity of suicide attempts
ArticleAbstract: Aim: Among people who die by suicide, an increased frequency of CYP2D6 active gene multiplication haPalabras claves:CYP2D6, severity of suicide attempt, ultrarapid metabolizerAutores:Adrián LLerena, Baca-Garca E., Blasco-Fontecilla H., Dorado P., Penãs-Lledó E.M., Vaquero-Lorenzo C.Fuentes:scopusCYP2D6 polymorphism and mental and personality disorders in suicide attempters
ArticleAbstract: Prior studies on the association between the CYP2D6 polymorphism and suicide did not explore whetherPalabras claves:Autores:Adrián LLerena, Baca-García E., Blasco-Fontecilla H., Dorado P., Penãs-Lledó E.M., Saiz-Ruiz J., Vaquero-Lorenzo C.Fuentes:scopusAssociation of common genetic variants with risperidone adverse events in a Spanish schizophrenic population
ArticleAbstract: Risperidone non-compliance is often high due to undesirable side effects, whose development is in paPalabras claves:Adverse events, Antipsychotic, pharmacogenetics, RisperidoneAutores:Abad-Santos F., Adrián LLerena, Almoguera B., Ayuso C., Baca-García E., Dal-Ré R., Dorado P., Fernandez-Piqueras J., Lopez-Castroman J., Riveiro-Alvarez R., Vaquero-Lorenzo C.Fuentes:scopusCYP2D6 poor metabolizer status might be associated with better response to risperidone treatment
ArticleAbstract: The variability in the antipsychotic response is, to some extent, genetically determined. Several stPalabras claves:CYP2D6, EFFECTIVENESS, MDR1, pharmacogenetics, Risperidone, SchizophreniaAutores:Abad-Santos F., Adrián LLerena, Almoguera B., Ayuso C., Baca-García E., Dal-Ré R., Dorado P., Fernandez-Piqueras J., Lopez-Castroman J., Riveiro-Alvarez R., Vaquero-Lorenzo C.Fuentes:scopusEvaluating a newly developed pharmacogenetic array: Screening in a Spanish population
ArticleAbstract: Aims: How genes affect the response in a patient to a given medication is still poorly understood; tPalabras claves:accuracy, CYP2D6, PHARMAChip array ®, pharmacogenetics, sensitivity, SLC6A4, Specificity, successful genotyping rateAutores:Abad-Santos F., Adrián LLerena, Almoguera B., Ayuso C., Dal-Ré R., Dorado P., Fernandez-Piqueras J., Gomez-Dominguez B., Lopez-Rodriguez R., Riveiro-Alvarez R., Vaquero-Lorenzo C.Fuentes:scopus